AMGN.BA Amgen Inc.

Healthcare Drug Manufacturers - General Buenos Aires Exchange
25,280 ARS
Close of Oct 29, 2026
15,159 25,280
Market cap
ARS 2.73T
P/E
0.2x
P/B
0.15x
ROE
71.8%
Dividend yield
1.93%
Fundamental score
2.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AMGN.BA undervalued?

Graham number

The Graham number of Amgen Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amgen Inc. fundamental analysis

12 of 22 checks passed

ROE 2/2

High return on equity (71.8%), above 20%.

ROA 1/1

Return on assets (8.8%) is above the industry median (7.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (87.9%) is below the industry median (87.9%).

Revenue Growth 2/2

Revenue grew 11.8% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (443.7%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 0/1

EBIT is 4.6x against interest expense, below 5x.

PE vs Market 1/1

PE (0.2x) is below the market median (6.7x).

PE vs Industry 1/1

PE (0.2x) is below the industry median (12.1x).

PBV 1/1

Price to book (0.1x) is below the industry median (1.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 2/2

Dividend yield (295.9%) is in the top 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 66.5%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Amgen Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…

Full company profile